Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys.

The powerful trophic effects that glial cell line-derived neurotrophic factor (GDNF) exerts on midbrain dopamine neurones suggest its use in treating Parkinson's disease. However, some important questions remain about the possible therapeutic applications of GDNF. Here we demonstrate that the chronic infusion of 5 or 15 micro g/day GDNF into the lateral ventricle or the striatum, using programmable pumps, promotes restoration of the nigrostriatal dopaminergic system and significantly improves motor functions in rhesus monkeys with neural deficits modelling the terminal stages of Parkinson's disease. The functional improvements were associated with pronounced upregulation and regeneration of nigral dopamine neurones and their processes innervating the striatum. When compared with vehicle recipients, these functional improvements were associated with (i) >30% bilateral increase in nigral dopamine neurone cell size; (ii) >20% bilateral increase in the number of nigral cells expressing the dopamine marker tyrosine hydroxylase; (iii) >70 and >50% bilateral increase in dopamine metabolite levels in the striatum and the pallidum, respectively; (iv) 233 and 155% increase in dopamine levels in the periventricular striatal region and the globus pallidus, respectively, on the lesioned side; and (v) a five-fold increase in tyrosine hydroxylase-positive fibre density in the periventricular striatal region on the lesioned side. In addition, chronic GDNF treatment did not induce the side-effects generally associated with chronic administration of levodopa, the most widely used treatment for Parkinson's disease. Thus, the results suggest that the prolonged and controlled delivery of GDNF into the brain could be used to intervene in long-term neurodegenerative disease processes like Parkinson's disease. Additional studies are required to determine the potential differences between chronic, intraventricular and intraputamenal (or intranigral) delivery of GDNF to maximize the efficacy of infusion treatments.

[1]  Don M. Gash,et al.  Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys , 1995, Neurobiology of Aging.

[2]  W. Cass,et al.  GDNF Selectively Protects Dopamine Neurons over Serotonin Neurons Against the Neurotoxic Effects of Methamphetamine , 1996, The Journal of Neuroscience.

[3]  B. Davidson,et al.  Dopaminergic Neurons Protected from Degeneration by GDNF Gene Therapy , 1997, Science.

[4]  Timothy Sendera,et al.  Clinicopathological findings following intraventricular glial‐derived neurotrophic factor treatment in a patient with Parkinson's disease , 1999, Annals of neurology.

[5]  Wiklund Ra,et al.  First of two parts , 1997 .

[6]  A. Björklund,et al.  Parkinson disease gene therapy moves toward the clinic , 2000, Nature Medicine.

[7]  E. Domino,et al.  MPTP-Induced Hemiparkinsonism in Nonhuman Primates 6–8 Years after a Single Unilateral Intracarotid Dose , 1998, Experimental Neurology.

[8]  K. Jellinger,et al.  Overview of morphological changes in Parkinson's disease. , 1987, Advances in neurology.

[9]  A. Lang,et al.  Parkinson's disease. First of two parts. , 1998, The New England journal of medicine.

[10]  K. Jellinger.  Parkinson’s Disease. Methods and Protocols , 2001 .

[11]  Zhiming Zhang,et al.  Neuroprotective and neurorestorative properties of GDNF , 1998, Annals of neurology.

[12]  D. Jacobowitz,et al.  Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1986, Life sciences.

[13]  G. Gerhardt,et al.  Chronic Intracerebral Delivery of Trophic Factors via a Programmable Pump as a Treatment for Parkinsonism. , 2001, Methods in molecular medicine.

[14]  B J Hoffer,et al.  Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys , 1995, The Journal of comparative neurology.

[15]  D. Hilt,et al.  Topographical distribution of [125I]-glial cell line-derived neurotrophic factor in unlesioned and MPTP-lesioned rhesus monkey brain following a bolus intraventricular injection , 1998, Brain Research.

[16]  A. Granholm,et al.  6-Hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra neurons of the rat , 1996, Experimental Brain Research.

[17]  D. Hilt,et al.  Glial cell line–derived neurotrophic factor–levodopa interactions and reduction of side effects in parkinsonian monkeys , 1997, Annals of neurology.

[18]  A. Björklund,et al.  Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease , 1997, Neuroscience.

[19]  J. Ridet,et al.  Lentiviral Vectors as a Gene Delivery System in the Mouse Midbrain: Cellular and Behavioral Improvements in a 6-OHDA Model of Parkinson's Disease Using GDNF , 2000, Experimental Neurology.

[20]  A. Björklund,et al.  Long-Term rAAV-Mediated Gene Transfer of GDNF in the Rat Parkinson's Model: Intrastriatal But Not Intranigral Transduction Promotes Functional Regeneration in the Lesioned Nigrostriatal System , 2000, The Journal of Neuroscience.

[21]  P. Jenner,et al.  Glial cell line-derived neurotrophic factor concentration dependently improves disability and motor activity in MPTP-treated common marmosets. , 2001, European journal of pharmacology.

[22]  L. Olson,et al.  Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[23]  M. Herkenham,et al.  Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: An in vivo autoradiographic study , 1991, Neuroscience.

[24]  B. Hoffer,et al.  Functional recovery in parkinsonian monkeys treated with GDNF , 1996, Nature.

[25]  J. Bloch,et al.  Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. , 2000, Science.

[26]  D. Hilt,et al.  Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys. , 1997, The Journal of pharmacology and experimental therapeutics.

[27]  C. Gross,et al.  Neurogenesis in Adult Mammals: Some Progress and Problems , 2002, The Journal of Neuroscience.

[28]  Shelley R. Winn,et al.  Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms , 1995, Experimental Neurology.

[29]  L. Olson,et al.  Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo , 1995, Nature.

[30]  Z. Zhang,et al.  Developing a stable bilateral model of parkinsonism in rhesus monkeys , 1993, Neuroscience.

[31]  L. Olson.  Combating Parkinson's Disease--Step Three , 2000, Science.

[32]  Y. Smith,et al.  Anatomy of the dopamine system in the basal ganglia , 2000, Trends in Neurosciences.

[33]  B. Davidson,et al.  Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat , 1999, Gene Therapy.

[34]  A. Björklund,et al.  Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease , 2001, European Journal of Neuroscience.

[35]  A. Lang,et al.  Parkinson's disease. Second of two parts. , 1998, The New England journal of medicine.

[36]  E. Bézard,et al.  Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey , 2000, Journal of Neuroscience Methods.

[37]  S. Kish,et al.  Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.

[38]  M. Korc,et al.  In vivo induction of massive proliferation, directed migration, and differentiation of neural cells in the adult mammalian brain. , 2000, Proceedings of the National Academy of Sciences of the United States of America.